ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Hoffmann-La Roche and CSPC Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Hoffmann-La RocheCSPC Pharmaceutical Group
studies on the registry2,744355
open to participants now115170
phase 3 studies under way9564
reach primary completion within a year7755
programswith a study of their own in two years80+25 named only68+3 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseHoffmann-La RocheCSPC Pharmaceutical Group
Phase 1

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. Anti-CDH17 Antibody-drug Conjugate HS-20110phase 1

and 28 more — sign in to see them all

41%

CSPC Pharmaceutical Group: 16 of its 68 programs at phase 1

  1. JMT206phase 1
  2. SYH2082phase 1
  3. JMT106phase 1
  4. paclitaxel cationic liposome for injectionphase 1
  5. palbociclibphase 1

and 11 more — sign in to see them all

24%
Phase 2

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%

CSPC Pharmaceutical Group: 26 of its 68 programs at phase 2

  1. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2
  2. SYS6006 COVID-19 vaccinephase 2
  3. ATM Inhibitor SYH2051phase 2
  4. SYH2069phase 2
  5. SYH2070phase 2

and 21 more — sign in to see them all

38%
Phase 3

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%

CSPC Pharmaceutical Group: 25 of its 68 programs at phase 3

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. enlonstobartphase 3
  4. becotatugphase 3
  5. anbenitamabphase 3

and 20 more — sign in to see them all

37%
Approved, new studies

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

CSPC Pharmaceutical Group: 1 of its 68 programs at approved, new studies

  1. Tenecteplaseapproved, new study
1%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Hoffmann-La Roche28 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. emicizumabapproved, new study · Nov 19 · NCT05181618
  2. nivegacetorphase 2 · Nov 19 · NCT06402838
  3. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289
  2. cevostamabphase 3 · Feb 26 · NCT05535244

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 1 program whose next study reaches primary completion

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
CSPC Pharmaceutical Group39 readouts · 6 phase 3

CSPC Pharmaceutical Group, Nov ’26: 3 programs whose next study reaches primary completion

  1. SYH2061phase 1 · Nov 24 · NCT07241910
  2. Anti-EGFR Antibody-drug Conjugate CPO301phase 3 · Nov 30 · NCT07256509
  3. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2 · Nov 30 · NCT07280832

CSPC Pharmaceutical Group, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. anbenitamabphase 3 · Dec 16 · NCT06747338
  2. Docetaxelphase 3 · Dec 16 · NCT06747338
  3. glumetinibphase 3 · Dec 25 · NCT06525350
  4. paliperidoneno phase · Dec 31 · NCT07493551
  5. SYH2059phase 2 · Dec 31 · NCT07510958

and 1 more — sign in to see them all

CSPC Pharmaceutical Group, Jan ’27: 4 programs whose next study reaches primary completion

  1. SYH2056phase 1 · Jan 30 · NCT07771777
  2. SYH2082phase 1 · Jan 30 · NCT07532655
  3. SYS6005phase 1 · Jan 30 · NCT06958679
  4. SYH2062phase 2 · Jan 31 · NCT07940075

CSPC Pharmaceutical Group, Feb ’27: 4 programs whose next study reaches primary completion

  1. SYH2072phase 2 · Feb 1 · NCT07647783
  2. SYH2092phase 1 · Feb 9 · NCT07776041
  3. JMT206phase 1 · Feb 28 · NCT07840729
  4. SYS6040phase 1 · Feb 28 · NCT06970795

CSPC Pharmaceutical Group, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. A zoster mRNA vaccine SYS6017phase 2 · Mar 10 · NCT07354659
  2. becotatugphase 3 · Mar 26 · NCT06380348
  3. SYS6041phase 2 · Mar 28 · NCT07744763

CSPC Pharmaceutical Group, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. enlonstobartphase 3 · Apr 0 · NCT06136988
  2. CPO-107phase 2 · Apr 1 · NCT07029139
  3. SYHX1901phase 3 · Apr 28 · NCT06943950
  4. SYH2070phase 2 · Apr 30 · NCT07695597
  5. SYH2085phase 2 · Apr 30 · NCT07798193

CSPC Pharmaceutical Group, May ’27: 1 program whose next study reaches primary completion

  1. anbenitamab repodatecanphase 3 · May 29 · NCT07545044

CSPC Pharmaceutical Group, Jun ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. ATM Inhibitor SYH2051phase 2 · Jun 15 · NCT06775236
  2. bempedoic acidphase 3 · Jun 30 · NCT07623915

CSPC Pharmaceutical Group, Jul ’27: 4 programs whose next study reaches primary completion

  1. ocankitugphase 3 · Jul 1 · NCT07418736
  2. SYH2053phase 3 · Jul 15 · NCT07938034
  3. SYS6045phase 2 · Jul 30 · NCT07122063
  4. CHO cellphase 2 · Jul 31 · NCT07892989

CSPC Pharmaceutical Group, Aug ’27: 2 programs whose next study reaches primary completion

  1. SYHX2008phase 3 · Aug 1 · NCT06505395
  2. JMT203phase 2 · Aug 14 · NCT06868849

CSPC Pharmaceutical Group, Sep ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Aripiprazoleno phase · Sep 5 · NCT07547384
  2. SYH2069phase 2 · Sep 28 · NCT07796477
  3. Tenecteplaseapproved, new study · Sep 30 · NCT07201688

CSPC Pharmaceutical Group, Oct ’27: 2 programs whose next study reaches primary completion

  1. palbociclibphase 1 · Oct 0 · NCT06941142
  2. Sirolimusphase 3 · Oct 0 · NCT06941142
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

CSPC Pharmaceutical Group

New programs 6

  • SYH9061phase 2 · first study · Nov 2 · Idiopathic Pulmonary Fibrosis
  • SYS6062phase 2 · first study · Oct 20 · Stomach Neoplasms
  • CHO cellphase 2 · first study · Oct 19 · COVID-19
  • SYH2066phase 2 · first study · Oct 11 · Respiratory Syncytial Virus Infections
  • Generic Drugphase 3 · first study · Sep 28 · Triple Negative Breast Neoplasms
  • SYS6088phase 2 · first study · Sep 20 · Neoplasms

Reached a new phase 3

  • SYH2072phase 2 · Oct 28 · Hyperaldosteronism
  • SYH2069phase 2 · Aug 25 · Obesity
  • SYH2085phase 2 · Aug 25 · Influenza, Human

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 30 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionHoffmann-La RocheCSPC Pharmaceutical Group
Breast Neoplasmsboth · compare here

Hoffmann-La Roche in Breast Neoplasms: 6 programs

  1. inavolisibphase 3
  2. giredestrantphase 3
  3. bizrolertinibphase 3
  4. vustanaciclibphase 2
  5. GDC-0587phase 1

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Breast Neoplasms in search

CSPC Pharmaceutical Group in Breast Neoplasms: 10 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. anbenitamabphase 3
  4. Sirolimusphase 3
  5. anbenitamab repodatecanphase 3

and 5 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Breast Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Hoffmann-La Roche in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. divarasibphase 3
  2. tambotatug pelitecanphase 2
  3. AQUA07phase 1
  4. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Non-Small-Cell Lung in search

CSPC Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. enlonstobartphase 3
  4. becotatugphase 3
  5. glumetinibphase 3

and 5 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Obesityboth · compare here

Hoffmann-La Roche in Obesity: 5 programs

  1. enicepatidephase 3
  2. petrelintidephase 3
  3. emugrobartphase 3
  4. tifeglipronphase 2
  5. HM17321no phase

Their studies: Hoffmann-La Roche’s studies of Obesity in search

CSPC Pharmaceutical Group in Obesity: 5 programs

  1. edaglutide alfaphase 3
  2. SYH2069phase 2
  3. SYH2082phase 1
  4. SYH2092phase 1
  5. SYH9017phase 1

Their studies: CSPC Pharmaceutical Group’s studies of Obesity in search

Colorectal Neoplasmsboth · compare here

Hoffmann-La Roche in Colorectal Neoplasms: 5 programs

  1. inavolisibphase 3
  2. divarasibphase 3
  3. autogene cevumeranphase 2
  4. Lead Pb 203-DOTAMphase 1
  5. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Colorectal Neoplasms in search

CSPC Pharmaceutical Group in Colorectal Neoplasms: 4 programs

  1. becotatugphase 3
  2. anbenitamab repodatecanphase 3
  3. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2
  4. sintilimabphase 2

Their studies: CSPC Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Neoplasmsboth · compare here

Hoffmann-La Roche in Neoplasms: 4 programs

  1. inavolisibphase 3
  2. lorlatinibphase 1
  3. Pan-RAS Inhibitor RG6505phase 1
  4. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Neoplasms in search

Stomach Neoplasmsboth · compare here

Hoffmann-La Roche in Stomach Neoplasms: 1 program

  1. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Stomach Neoplasms in search

CSPC Pharmaceutical Group in Stomach Neoplasms: 7 programs

  1. Docetaxelphase 3
  2. enlonstobartphase 3
  3. anbenitamabphase 3
  4. anbenitamab repodatecanphase 3
  5. trastuzumab envedotinphase 3

and 2 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Stomach Neoplasms in search

Carcinoma, Hepatocellularboth · compare here

Hoffmann-La Roche in Carcinoma, Hepatocellular: 1 program

  1. codrituzumabphase 2

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Hepatocellular in search

Renal Insufficiencyboth · compare here

Hoffmann-La Roche in Renal Insufficiency: 3 programs

  1. petrelintidephase 3
  2. tifeglipronphase 2
  3. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Renal Insufficiency in search

CSPC Pharmaceutical Group in Renal Insufficiency: 3 programs

  1. Sirolimusphase 3
  2. SYH2053phase 3
  3. aprocitentanphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Renal Insufficiency in search

Diabetes Mellitus, Type 2both · compare here

Hoffmann-La Roche in Diabetes Mellitus, Type 2: 3 programs

  1. enicepatidephase 3
  2. emugrobartphase 3
  3. tifeglipronphase 2

Their studies: Hoffmann-La Roche’s studies of Diabetes Mellitus, Type 2 in search

CSPC Pharmaceutical Group in Diabetes Mellitus, Type 2: 2 programs

  1. edaglutide alfaphase 3
  2. SYH2069phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Ovarian Neoplasmsboth · compare here

Hoffmann-La Roche in Ovarian Neoplasms: 1 program

  1. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Ovarian Neoplasms in search

CSPC Pharmaceutical Group in Ovarian Neoplasms: 4 programs

  1. enlonstobartphase 3
  2. anbenitamab repodatecanphase 3
  3. trastuzumab envedotinphase 3
  4. SYS6041phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Ovarian Neoplasms in search

COVID-19both · compare here

Hoffmann-La Roche in COVID-19: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of COVID-19 in search

CSPC Pharmaceutical Group in COVID-19: 3 programs

  1. SYS6006 COVID-19 vaccinephase 2
  2. CHO cellphase 2
  3. palbociclibphase 1

Their studies: CSPC Pharmaceutical Group’s studies of COVID-19 in search

Dermatitis, Atopicboth · compare here

Hoffmann-La Roche in Dermatitis, Atopic: 3 programs

  1. afimkibartphase 3
  2. astegolimabphase 3
  3. Cyclosporineapproved, new study

Their studies: Hoffmann-La Roche’s studies of Dermatitis, Atopic in search

CSPC Pharmaceutical Group in Dermatitis, Atopic: 1 program

  1. ocankitugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Dermatitis, Atopic in search

Show all 30

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Hoffmann-La Roche 40 of 80 · CSPC Pharmaceutical Group 25 of 68 programs (34 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Hoffmann-La Roche: 25, CSPC Pharmaceutical Group: 3).